Liu Bao-Jiang, Gao Song, Zhu Xu, Guo Jian-Hai, Kou Fu-Xin, Liu Shao-Xing, Zhang Xin, Wang Xiao-Dong, Cao Guang, Chen Hui, Liu Peng, Xu Hai-Feng, Gao Qin-Zong, Yang Ren-Jie
Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education), 52 Fucheng Road, Haidian District, Beijing, 100142, China.
Immunotherapy. 2021 Dec;13(17):1395-1405. doi: 10.2217/imt-2021-0192. Epub 2021 Oct 5.
We investigated the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKIs) for advanced hepatocellular carcinoma (HCC). This retrospective study included HCC patients treated with HAIC, TKIs and anti-PD-1 antibodies between May 2019 and November 2020 in our hospital. Primary end points were progression-free survival and safety. Twenty-seven advanced HCC patients were analyzed. The median follow-up was 12.9 months (range: 4.0-24.0 months) and the median progression-free survival was 10.6 months. The objective response rate and disease control rate were 63.0 and 92.6%, respectively. No treatment-related deaths occurred. In patients with advanced HCC, treatment with HAIC, anti-PD-1 antibodies and oral TKIs was effective and safe.
我们研究了肝动脉灌注化疗（HAIC）联合抗PD-1免疫疗法及酪氨酸激酶抑制剂（TKIs）治疗晚期肝细胞癌（HCC）的疗效和安全性。这项回顾性研究纳入了2019年5月至2020年11月在我院接受HAIC、TKIs及抗PD-1抗体治疗的HCC患者。主要终点为无进展生存期和安全性。对27例晚期HCC患者进行了分析。中位随访时间为12.9个月（范围：4.0 - 24.0个月），中位无进展生存期为10.6个月。客观缓解率和疾病控制率分别为63.0%和92.6%。未发生与治疗相关的死亡。对于晚期HCC患者，HAIC、抗PD-1抗体及口服TKIs联合治疗有效且安全。
